Fundraising FoxArdelyx
Fremont, US · 3 known investors
Find your way into Ardelyx
Sign up to see every warm intro you have to Ardelyx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ardelyx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs. It focuses on therapeutic areas including chronic kidney disease with hyperphosphatemia and irritable bowel syndrome with constipation.
Founders & leadership
MK
Mark KaufmannExecutive
EG
Elizabeth GrammerExecutiveElizabeth Grammer is a lawyer and senior executive with over 30 years of experience in the biopharmaceutical industry, having held leadership roles in legal, compliance, intellectual property, government affairs, and human resources. She currently serves as Senior Advisor to Ardelyx, Inc.
JC
Jeremy CaldwellExecutive
MR
Mike RaabExecutive
Board
DM
AJ
Annalisa JenkinsBoard director
RR
Richard RodgersBoard director
GR
Gordon RingoldBoard director
PG
Peter G. SchultzBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$187.8M disclosed across 2 rounds · 2015–2016
▶$110MraisedAug 2016 · 31 investors · PharmaceuticalsRule 506(b)
▶$110MraisedAug 2016 · 31 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Annalisa JenkinsDirector
- Paul KornerExecutive Officer
- David MottDirector
- David RosenbaumExecutive Officer
- Elizabeth GrammerExecutive Officer
- Michael RaabExecutive Officer, Director
- Gordon RingoldDirector
- Robert BazemoreDirector
- Richard RodgersDirector
- Jeff JacobsExecutive Officer
- Mark KaufmannExecutive Officer
- William Bertrand, Jr.Director
- Jeremy CaldwellExecutive Officer
- Offering amount
- $110M
- Amount sold
- $110M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$77.8MraisedJun 2015 · 11 investors · PharmaceuticalsRule 506(b)
▶$77.8MraisedJun 2015 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Annalisa JenkinsDirector
- Mark KaufmannExecutive Officer
- Elizabeth GrammerExecutive Officer
- Richard RodgersDirector
- Gordon RingoldDirector
- Peter G. SchultzDirector
- David MottDirector
- David RosenbaumExecutive Officer
- Jeremy CaldwellExecutive Officer
- Michael RaabExecutive Officer, Director
- Offering amount
- $108M
- Amount sold
- $77.8M
- Sales commissions
- $2.5M
- Placement agents
- Leerink Partners LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Ardelyx do?
- Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs. It focuses on therapeutic areas including chronic kidney disease with hyperphosphatemia and irritable bowel syndrome with constipation.
- Who are Ardelyx's investors?
- Ardelyx's investors include Foresite Capital, HEALTHCARE ROYALTY PARTNERS, New Enterprise Associates (NEA).
- How much funding has Ardelyx raised?
- Ardelyx has disclosed $187.8M raised across 2 rounds.
- Where is Ardelyx headquartered?
- Ardelyx is headquartered in Fremont, US.